PARP inhibitors in BRCA gene-mutated ovarian cancer and beyond.

Abstract

Poly(ADP-ribose)polymerase (PARP) inhibitors are showing considerable promise for the treatment of BRCA mutation-associated ovarian and breast cancer. This approach exploits a synthetic lethal strategy to target the specific DNA repair pathway in cancers that harbor mutations in the BRCA1 or BRCA2 genes. Accumulating evidence suggests that PARP inhibitors may have a wider application in the treatment of sporadic, high-grade serous ovarian cancers and other cancers including endometrial cancer. In this review, we discuss the clinical development of PARP inhibitors in ovarian cancer and explore challenges that need to be addressed if the full potential of these agents is to be realized.

• Authors: Susana Banerjee, Stan Kaye
• Journal: Current oncology reports (Curr Oncol Rep) Vol. 13 Issue 6 Pg. 442-9 (Dec 2011) ISSN: 1534-6269 [Electronic] United States
• PMID: 21913063 (Publication Type: Journal Article, Review)

Chemical References

• Antineoplastic Agents
• Enzyme Inhibitors
• Poly(ADP-ribose) Polymerase Inhibitors

Topics

• Antineoplastic Agents (therapeutic use)
• Enzyme Inhibitors (therapeutic use)
• Female
• Genes, BRCA1
• Genes, BRCA2
• Genetic Predisposition to Disease
• Humans
• Mutation
• Ovarian Neoplasms (drug therapy, genetics)
• Poly(ADP-ribose) Polymerase Inhibitors